Pacilitaxel in association with gemcitabine for anthracycine-resistant advanced breast cancer
- VernacularTitle:紫杉醇加吉西他滨治疗蒽环类耐药的晚期乳腺癌
- Author:
Qingfeng FANG
;
Zhihua SHAO
;
Wei LIN
;
Jing JIN
;
Yueyuan JIANG
;
Ruiyuan LU
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Drug therapy;
Paclitaxel;
Gemcitabine
- From:
Chinese Journal of General Surgery
2001;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect and safety of combined therapy of paclitaxel and gemcitabine for anthracycine(ANT)-resistant advanced breast cancer(ABC).MethodsFrom May 2000 to Aug 2004,twenty six patients with ANT-resistant ABC were treated with this combined regime.The median chemotherapy cycles were 2.5(range from 2 to 3 cycles).ResultsOf 26 patients, there were 3 complete(11.5%) and 11 partial(42.3%) responses for an overall response rate of 53.8%. Eight cases remained stable (30.8%) and 4 progressive (15.4%). The median survival time was 18 months. The median time to progression was 7 months. The main toxic reaction included bone marrow depression, liver function damage, alopecia, mucositis and peripheral neurotoxicity. ConclusionsCombined medication of gemcitabine and paclitaxel is effective in therapy of ANT-resistant advanced breast cancer with acceptable toxicity.
